Ionis Pharmaceuticals, Inc. has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. The companies have a broad strategic collaboration focused on leveraging antisense technology to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development.    “The recent FDA approval of SPINRAZA highlight...